Ariel Small/Mid Cap Value Q2 2026 Portfolio Activity

The Ariel Small/Mid Cap Value Composite rose +15.08% gross of fees (+14.95% net of fees) in the quarter, falling short of both the Russell 2500 Value Index's +18.50% return and the +20.26% gain posted by the Russell 2500 Index. Live entertainment, media, and technology company, Sphere Entertainment Co. was the top contributor during the quarter on solid earnings and improving operating fundamentals. Shares of Prestige Consumer Healthcare moved lower following disappointing earnings, driven primarily by ongoing supply constraints in its eye care segment and extended lead times in the Middle East.

Seeking Alpha • Jul 23, 2026

Ariel Investments Small Cap Value Q2 2026 Portfolio Activity

Lindblad Expeditions' booking trends remained encouraging, with solid visibility into future demand supported by momentum in both near- and longer-term travel. Knowles Corporation's performance was propelled by solid execution across segments, with Precision Devices benefiting from robust demand across diverse applications and its positioning for accelerated growth. Oil services company Core Laboratories declined over the quarter as geopolitical tensions, weather disruptions and softer U.S. land drilling activity impacted performance.

Seeking Alpha • Jul 20, 2026

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026

BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, August 6, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 6, 2026.

PRNewsWire • Jul 8, 2026

Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?

HAE's Plasma franchise and NexSys PCS momentum may support growth, but heavy debt and competitive pressure remain key concerns.

Zacks Investment Research • Jul 3, 2026

Pharvaris Announces Annual General Meeting of Shareholders

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).

GlobeNewsWire • Jun 11, 2026

Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 8, 2026

Haemonetics Updates Financial Reporting Segments

BOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced an update to its reportable segment structure to better align external financial reporting with how the Company manages its business and allocates resources. Under the new structure, Haemonetics will transition from three reportable segments to two.

PRNewsWire • Jun 5, 2026

Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference

BOSTON, June 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.webcasts.com/starthere.jsp?ei=1766065&tp_key=0b16b4b62d&tp_special=8 A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.

PRNewsWire • Jun 2, 2026

Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends

Examine the evolution of Haemonetics' (HAE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Zacks Investment Research • May 22, 2026

Is the Options Market Predicting a Spike in Haemonetics Stock?

Investors need to pay close attention to GBTG stock based on the movements in the options market lately.

Zacks Investment Research • May 13, 2026